Online citations, reference lists, and bibliographies.
← Back to Search

Large Porous Particles For Pulmonary Drug Delivery.

D. Edwards, J. Hanes, G. Caponetti, J. Hrkach, A. Benjebria, M. L. Eskew, J. Mintzes, D. Deaver, N. Lotan, R. Langer
Published 1997 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
A new type of inhalation aerosol, characterized by particles of small mass density and large size, permitted the highly efficient delivery of inhaled therapeutics into the systemic circulation. Particles with mass densities less than 0.4 gram per cubic centimeter and mean diameters exceeding 5 micrometers were inspired deep into the lungs and escaped the lungs' natural clearance mechanisms until the inhaled particles delivered their therapeutic payload. Inhalation of large porous insulin particles resulted in elevated systemic levels of insulin and suppressed systemic glucose levels for 96 hours, whereas small nonporous insulin particles had this effect for only 4 hours. High systemic bioavailability of testosterone was also achieved by inhalation delivery of porous particles with a mean diameter (20 micrometers) approximately 10 times that of conventional inhaled therapeutic particles.
This paper references
J. Aerosol Sci
J W Tom (1991)
Biomaterials Proc. Soc. Exp. Med. J. Controlled Release
H Kawaguchi (1961)
J. Pharm. Sci
F Komada (1994)
February REPORTS www.sciencemag.org ⅐ SCIENCE ⅐
(1997)
Topics in Pharmaceutical Sciences Eds. (Medpharm Scientific
I Gonda (1991)
Crit. Rev. Ther. Drug Carrier Syst
R Niven (1995)
Perez de la Cruz for helpful technical assistance
J We
10.1016/S0169-409X(97)90003-X
Adv. Drug Delivery Rev.
F. Welt (1997)
10.1021/MA00117A055
Synthesis of Poly(L-lactic acid-co-L-lysine) Graft Copolymers
J. Hrkach (1995)
Pharm. Res
F Y Liu (1993)
10.1016/s0165-6147(96)90065-6
Remington:the science and practice of pharmacy
A. R. Gennaro (1995)
Pharm. Res
P Colthorpe (1992)
Pharm. Res
S Cohen (1991)
Bioavailability was determined as (AUC inhaled / AUC subcutaneous ) ϫ 100, where AUC is area under the curve
Biopharm. Sci. Pharm. Res
D Ganderton (1990)
Ann. N.Y. Acad. Sci
O Einarsson (1995)
10.1111/j.1749-6632.1995.tb32317.x
Interleukin‐11 in Respiratory Inflammation
O. Einarsson (1995)
Aerosols and the Lung: Clinical and Experimental Aspects
S. Clarke (1984)
PLGA particles were made using the double-and single-emulsification solvent evaporation procedures
D A Edwards
Int. J. Pharm
Le Corre (1994)
10.1023/A:1015851521551
The Pharmacokinetics of Pulmonary-Delivered Insulin: A Comparison of Intratracheal and Aerosol Administration to the Rabbit
P. Colthorpe (2004)
10.1126/SCIENCE.2218494
New methods of drug delivery.
R. Langer (1990)
10.1002/JPS.2600830621
Intratracheal delivery of peptide and protein agents: absorption from solution and dry powder by rat lung.
Fusao Komada (1994)
10.1016/0142-9612(86)90091-8
Phagocytosis of latex particles by leucocytes. I. Dependence of phagocytosis on the size and surface potential of particles.
H. Kawaguchi (1986)
Crit. Rev. Ther. Drug Carrier Syst
I Gonda (1990)
10.1615/CRITREVTHERDRUGCARRIERSYST.V12.I2-3.20
Delivery of biotherapeutics by inhalation aerosol.
R. Niven (1995)
Supported by an NSF CAREER Grant (D.E., J.M.) and NIH grants GM26698 (R.L.) and HD29125 (R.L., J.H.)
J. Heidel (1997)
Microscopy Res. Tech
M B Warheit (1985)



This paper is referenced by
10.1016/j.addr.2020.07.006
Emerging trends in inhaled drug delivery
A. J. Hickey (2020)
10.1002/ppsc.201900447
Nano‐in‐Micro Sildenafil Dry Powder Formulations for the Treatment of Pulmonary Arterial Hypertension Disorders: The Synergic Effect of POxylated Polyurea Dendrimers, PLGA, and Cholesterol
Rita B. Restani (2020)
10.1007/s10494-018-9927-1
Targeted Drug Delivery to Upper Airways Using a Pulsed Aerosol Bolus and Inhaled Volume Tracking Method
Y. Ostrovski (2019)
10.1016/J.COLSURFA.2019.123720
Thermosensitive polysaccharide particles for pulmonary drug delivery
T. Sato (2019)
10.1002/(SICI)1097-4660(200001)75:1<42::AID-JCTB173>3.0.CO;2-C
Solvent effects on the controlled dense gas precipitation of model proteins
R. Thiering (2000)
10.1201/9780203009673
A Guide to Pharmaceutical Particulate Science
A. J. Hickey (2003)
10.1152/AJPLUNG.00260.2003
Alveolar macrophages are a primary barrier to pulmonary absorption of macromolecules.
C. Lombry (2004)
10.2165/00003088-200544030-00004
Respirable Microspheres for Inhalation
M. Sakagami (2005)
10.1016/J.JCONREL.2005.01.003
Novel sustained release microspheres for pulmonary drug delivery.
R. O. Cook (2005)
10.1016/J.JCONREL.2006.04.004
Triggered release of inhaled insulin from the agglomerated vesicles: pharmacodynamic studies in rats.
E. Karathanasis (2006)
10.1517/17425247.4.1.63
First approved inhaled insulin therapy for diabetes mellitus
R. Jani (2007)
Respirable microparticles of aminoglycoside antibiotics for pulmonary administration
C. Parlati (2009)
10.1039/c0cp00119h
Microfluidic characterization of sustained solute release from porous supraparticles.
V. Rastogi (2010)
10.1089/jamp.2010.0838
Pulmonary formulations: what remains to be done?
J. Weers (2010)
10.1007/978-1-4419-9745-6_15
Nanoparticles for Pulmonary Delivery
A. B. Watts (2011)
10.1016/j.jconrel.2010.12.006
Chitosan-interferon-β gene complex powder for inhalation treatment of lung metastasis in mice.
H. Okamoto (2011)
10.4155/tde.13.67
Mechanisms of absorption and elimination of drugs administered by inhalation.
Mariam Ibrahim (2013)
10.1007/s11095-007-9466-2
Core–shell Particles for the Dispersion of Small Polar Drugs and Biomolecules in Hydrofluoroalkane Propellants
Libo Wu (2007)
10.1038/nmat2344
Physical approaches to biomaterial design.
S. Mitragotri (2009)
10.1530/EJE.0.1390481
Hormone delivery: small synthetic molecular mimics.
J. Lopez-Liuchi (1998)
10.1016/j.jconrel.2011.02.030
Formulation and in vivo evaluation of sodium alendronate spray-dried microparticles intended for lung delivery.
L. Cruz (2011)
10.1016/j.addr.2014.05.001
Lipid-based carriers for pulmonary products: preclinical development and case studies in humans.
D. Cipolla (2014)
10.1016/j.ijpharm.2015.12.025
Design of PLGA-based depot delivery systems for biopharmaceuticals prepared by spray drying.
F. Wan (2016)
10.3109/02652048.2014.932029
The role of particle physico-chemical properties in pulmonary drug delivery for tuberculosis therapy
Ninell P Mortensen (2014)
10.1016/J.JDDST.2017.04.016
Well-designed microcapsules fabricated using droplet-based microfluidic technique for controlled drug release
Zexia Luo (2017)
10.1021/acsnano.6b00985
Particles with Tunable Porosity and Morphology by Controlling Interfacial Instability in Block Copolymer Emulsions.
K. Ku (2016)
10.1248/CPB.60.334
Development of dry salbutamol sulfate powder with high inhalation performance independent of inhalation patterns.
D. Hira (2012)
10.1007/s11095-015-1701-7
Distribution and Cellular Uptake of PEGylated Polymeric Particles in the Lung Towards Cell-Specific Targeted Delivery
T. Shen (2015)
10.1016/J.COLSURFA.2016.06.009
Analysis of cohesion forces between monodisperse microparticles with rough surfaces
A. Baldelli (2016)
10.1016/S0927-7765(99)00079-X
Gene transfection using biodegradable nanospheres: results in tissue culture and a rat osteotomy model
V. Labhasetwar (1999)
10.1016/S0168-3659(00)00362-X
Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance.
C. Bosquillon (2001)
10.1016/S0169-409X(01)00167-3
Microparticles for intranasal immunization.
M. Vajdy (2001)
See more
Semantic Scholar Logo Some data provided by SemanticScholar